AllPennyStocks.com NVO Stock: Why Morgan Stanley Is Bearish On Novo Nordisk Despite Its Weight-Loss Drug Opportunity
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

NVO Stock: Why Morgan Stanley Is Bearish On Novo Nordisk Despite Its Weight-Loss Drug Opportunity

Morgan Stanley downgraded Novo to ‘Underweight’ from ‘Equal Weight’ while keeping its $40 price target, a 7% downside from current levels.

Other Penny Stock Movers

SaaS Provider Surges 22% on Profitability Targets
BC Copper-Gold Explorer Surges 40% on Maiden Drill Visuals
Why Mining Giants Keep Buying the Ground Next Door
Most Popular
{{ index + 1 }}


Back to Top